Little House Capital LLC Has $1.47 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Little House Capital LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 85.3% during the fourth quarter, Holdings Channel reports. The firm owned 2,515 shares of the company’s stock after acquiring an additional 1,158 shares during the period. Little House Capital LLC’s holdings in Eli Lilly and Company were worth $1,466,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the stock. Lipe & Dalton bought a new position in Eli Lilly and Company in the fourth quarter valued at about $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company in the third quarter valued at about $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the third quarter worth approximately $35,000. Optiver Holding B.V. acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $36,000. Finally, Family CFO Inc acquired a new position in Eli Lilly and Company in the third quarter valued at approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the completion of the sale, the insider now directly owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Up 1.2 %

Shares of NYSE:LLY traded up $8.64 on Friday, reaching $733.51. The company had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. Eli Lilly and Company has a 52-week low of $380.77 and a 52-week high of $800.78. The firm’s 50 day simple moving average is $761.79 and its 200-day simple moving average is $666.67. The firm has a market capitalization of $696.95 billion, a PE ratio of 126.47, a PEG ratio of 1.60 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s revenue was up 28.1% on a year-over-year basis. During the same quarter last year, the business posted $2.09 EPS. As a group, analysts expect that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on LLY shares. Morgan Stanley upped their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Wells Fargo & Company lifted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Finally, Barclays lifted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.